Myositis Supportive Care Protocol

Autoimmune/Musculoskeletal DisordersLimited Evidence
6
supplements
2
Primary
4
Supporting
0
Grade A
31
Studies

Primary Stack

Core supplements with strongest evidence
2000-4000 IU daily (titrate to levels)

Often deficient in autoimmune diseases; supports immune modulation and muscle function

8 studies300 participants

Supports muscle energy and may help maintain muscle mass during disease activity

4 studies100 participants

Supporting Stack

Additional supplements for enhanced results
2-4g EPA+DHA daily

Anti-inflammatory properties; may help modulate immune response

5 studies150 participants
100-300mg daily

Supports mitochondrial function in muscle cells; antioxidant

4 studies100 participants
1000-1200mg daily

Supports bone health; corticosteroid treatment increases osteoporosis risk

6 studies200 participants
1.2-1.5g/kg/day total protein

Supports muscle protein synthesis and maintenance during inflammatory states

4 studies100 participants

How This Protocol Works

Simple Explanation

Myositis refers to a group of rare conditions characterized by chronic muscle inflammation, leading to muscle weakness. The main types are dermatomyositis, polymyositis, and inclusion body myositis.

TYPES:

•Dermatomyositis: Muscle weakness + skin rash
•Polymyositis: Muscle weakness without rash
•Inclusion Body Myositis (IBM): Slowly progressive; often older adults
•Juvenile myositis: Occurs in children

SYMPTOMS:

•Progressive muscle weakness (proximal muscles)
•Difficulty climbing stairs, rising from chairs
•Difficulty lifting arms overhead
•Fatigue
•Skin rashes (dermatomyositis)
•Swallowing difficulties
•Shortness of breath (if respiratory muscles affected)

CRITICAL: Myositis requires comprehensive medical management. This protocol is SUPPORTIVE ONLY.

MEDICAL TREATMENTS:

•Corticosteroids: First-line (prednisone)
•Immunosuppressants: Methotrexate, azathioprine, mycophenolate
•IVIG: For refractory cases
•Rituximab: For difficult cases
•Physical therapy: Essential for maintaining function

ASSOCIATED CONDITIONS:

•Interstitial lung disease (requires monitoring)
•Increased cancer risk (dermatomyositis in adults)
•Cardiac involvement (possible)
•Calcinosis (especially in children)

MONITORING:

•Muscle enzymes (CK, aldolase)
•Pulmonary function tests
•Cancer screening (dermatomyositis)
•Bone density (if on steroids)

* Vitamin D supports muscle function and immune modulation.

* Calcium is important for bone health on corticosteroids.

* Adequate protein helps maintain muscle mass.

Expected timeline: Medical treatment response varies (weeks to months). Supplements support overall health during treatment.

Clinical Perspective

Myositis: Inflammatory myopathies - dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM). Autoantibodies help classify and predict complications (anti-Jo-1, anti-Mi-2, anti-MDA5, etc.). Key features: proximal weakness, elevated CK, EMG abnormalities, muscle biopsy findings.

CRITICAL: Corticosteroids are first-line. Steroid-sparing agents: methotrexate, azathioprine, mycophenolate, rituximab, IVIG. IBM less responsive to immunotherapy. Screen for ILD (pulmonary function, HRCT). Malignancy screening in DM (especially adults). Physical therapy essential. Supplements address nutritional deficiencies and support muscle/bone health - adjunctive only.

* Vitamin D (B-grade): Immune modulation. Systematic review: (PMID: 28750270). 2000-4000 IU daily.

* Creatine (C-grade): Muscle energy. Review: (PMID: 28615996). 5-10g daily.

* Omega-3 (C-grade): Anti-inflammatory. Systematic review: (PMID: 27840029). 2-4g EPA+DHA daily.

* CoQ10 (C-grade): Mitochondrial support. Review: (PMID: 24268541). 100-300mg daily.

* Calcium (B-grade): Bone health. Guidelines: (PMID: 28332116). 1000-1200mg daily.

* Protein (C-grade): Muscle maintenance. Review: (PMID: 28698222). 1.2-1.5g/kg/day.

Assessment targets: Muscle strength (MMT), CK levels, functional status, PFTs, bone density.

Protocol notes: Corticosteroids: high-dose initially (1mg/kg), slow taper over months. Steroid-sparing: start early to minimize steroid exposure. IBM: progressive despite treatment; maintain function with PT. ILD: anti-MDA5 associated with rapidly progressive ILD; aggressive treatment needed. Malignancy: CT chest/abdomen/pelvis, age-appropriate cancer screening. PT/exercise: gentle during active disease; progressive as controlled. Dysphagia: assess swallowing; may need modified diet. Osteoporosis prevention: calcium, vitamin D, bisphosphonate if high risk. Calcinosis: difficult to treat; may try diltiazem. Autoantibodies: myositis-specific antibodies guide prognosis and monitoring.